Effect of panretinal photocoagulation combined with intravitreal Conbercept in the treatment of proliferative diabetic retinopathy with different stages
Author:
Corresponding Author:

Affiliation:

Clc Number:

Fund Project:

National Natural Science Foundation of China(No.82101164); Natural Science Foundation of Shandong Province, China(No.ZR2020QH148, ZR2021MH074, ZR2021MH152); Taishan Scholar Foundation of Shandong Province(No.tsqn202211344)

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    AIM: To investigate the effectiveness of panretinal photocoagulation(PRP)combined with intravitreal conbercept(IVC)for patients with different stages of proliferative diabetic retinopathy(PDR).

    METHODS: Retrospective study. The medical records for 100 patients(100 eyes)with PDR treated with PRP combined with IVC from January 2018 to June 2020 were reviewed, including 34 eyes with early PDR(group A), 43 with high-risk PDR(group B), and 23 with fibrovascular PDR(group C). The baseline information, best corrected visual acuity(BCVA), central macular thickness(CMT), the rate of vitrectomy and retinal detachment of the patients in the three groups at 1, 3, 6mo and the last follow-up after combination treatment were observed.

    RESULTS: The patients were followed up for 14.60±11.64mo(6-52mo), with a mean age of 54.22 ±9.32 years. We found 15 eyes(15.0%)who underwent vitrectomy after the combination treatment. The vitrectomy rates of the three groups were 2.9% in group A, 13.9% in group B, and 34.7% in group C. We found no instances of retinal detachment after the treatments. Most patients demonstrated improved BCVA and CMT values with the treatments.

    CONCLUSION: PRP combined with IVC is safe and effective in patients with different PDR stages.

    Reference
    Related
    Cited by
Get Citation

Tian-Hui Shan, Jia-Xuan Yu, Chun-Li Liu, et al. Effect of panretinal photocoagulation combined with intravitreal Conbercept in the treatment of proliferative diabetic retinopathy with different stages. Guoji Yanke Zazhi( Int Eye Sci) 2023;23(8):1242-1249

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:January 16,2023
  • Revised:May 08,2023
  • Adopted:
  • Online: July 25,2023
  • Published: